Expert Ratings for Tradeweb Markets

Within the last quarter, Tradeweb Markets (NASDAQ:TW) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…

Within the last quarter, Tradeweb Markets (NASDAQ:TW) has observed the following analyst ratings:

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 1 4 2 0 0
Last 30D 0 1 0 0 0
1M Ago 0 0 1 0 0
2M Ago 0 1 1 0 0
3M Ago 1 2 0 0 0

These 7 analysts have an average price target of $75.86 versus the current price of Tradeweb Markets at $70.89, implying upside.

Below is a summary of how these 7 analysts rated Tradeweb Markets over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock

price target chart

This current average represents a 1.26% decrease from the previous average price target of $76.83.

Stay up to date on Tradeweb Markets analyst ratings.

How Are Analyst Ratings Determined?

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Expert Ratings for Clean Harbors

Over the past 3 months, 4 analysts have published their opinion on Clean Harbors (NYSE:CLH) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

CLH

Read More

This Analyst Downgrades Bristol-Myers Squibb, Cautions Amid Product Launch And Revenue Concerns

BofA Securities downgraded Bristol-Myers Squibb & Co (NYSE: BMY), noting that initially, the analyst believed that Bristol's loss of exclusivity (LOEs) for drugs like Eliquis and Opdivo was widely understood and it was anticipated that new product lineup would compensate

BMY